Introduction
Selection of targeted therapies for cancer drug development has traditionally been based on the presence or absence of specific somatic mutations and this has been shown to be an effective strategy to improve patient outcomes (1) (2) (3) (4) . However, a large number of targeted drugs and other compounds that have anti-tumor properties have not been linked to specific mutations, or biomarkers, that could be used to predict their selective efficacy (5) . Although next-generation sequencing (NGS) allows researchers to rapidly and comprehensively profile tumor mutations, the vast majority of these data have not been useful in the clinical setting since only a small number of mutations have been used to inform prognosis or guide therapeutic decisions (6) (7) (8) .
Several computational approaches exist and have been implemented to predict the functional impact of mutations, and even to predict whether a specific mutation is a driver of the carcinogenesis process, based on several factors such as evolutionary conservation, predicted effects on protein structure and observed recurrence in existing cancer data sets (9) (10) (11) .
However, these computational predictions provide little insight into how cellular processes are altered as a consequence of the mutations. One strategy to assess whether or not specific mutations are influential on cellular processes is to determine whether or not a mutation induces a signature of gene expression changes (12). Gene expression signatures associated with an individual mutation could then be examined to characterize its cellular impact (13) and the signature could be used as a target for candidate drug therapies (14) . We have developed the Cancer in silico Drug Discovery (CiDD) platform for the purposes of characterizing tumors with specific mutations, or more generally tumors with specific clinicopathological or molecular characteristics, based on their putative effects on gene expression, and to identify candidate drugs to treat these tumors.
Here, we describe the general framework and integrated data sets of this novel platform. CiDD has been designed to generate hypotheses for the following three general problems: 1) to determine if particular clinical or molecular characteristics are associated with unique gene expression signatures; 2) to find candidate drugs to treat specific tumor subgroups based on these expression changes; and 3) to identify cell lines that resemble the tumors being studied for subsequent in vitro experimentation. In addition, to illustrate the use of CiDD, we have applied it to a clinically relevant context in cancer drug development. We report the in silico a poor prognosis and presents a therapeutic challenge (4, 15 
Materials and Methods
CiDD is a systematic drug discovery platform that integrates and analyzes large-scale cancer data sets with the primary goal of identifying candidate drugs and cell lines to be validated experimentally in vitro (see Figure 1) . The core data sets used by CiDD include The Cancer Genome Atlas (TCGA), the Connectivity Map (CMap) and the Cancer Cell Line Encyclopedia (CCLE). CiDD is purely computational and depends on publicly available clinical and experimental datasets, as well as annotation databases. CiDD is written in Python, has R package dependencies and is command-line driven allowing it to be integrated into bioinformatics pipelines. The software and code are freely available at http://scheet.org/software.
Data assembly
Required experimental data sets for performing CiDD analyses are TCGA (16) and CMap (14) .
CCLE (17) is required to identify cell-lines for subsequent experimentation. TCGA includes clinical, mutation and gene expression data for thousands of samples across multiple cancer types. CiDD provides commands to download, query and analyze these data. CMap is a collection of gene expression data for cell lines treated with small molecules paired with patternmatching algorithms that attempt to identify biologically functional connections between drugs and gene expression profiles (14) . CiDD utilizes CMap build 02, which contains more than 7,000 expression profiles representing the effects of 1,309 compounds. CCLE provides molecular profiles for 947 cancer cell lines which include DNA copy number, gene expression and DNA mutation data (17) .
The experimental data from CMap consists of rank-based gene expression values from the Affymetrix HG-U133A microarray. Thus, CMap is designed for the analysis of Affymetrix gene expression data only, which hinders using CMap with gene expression data collected from nonAffymetrix platforms. To overcome this limitation, CiDD transforms bulk-downloaded CMap data from Affymetrix probe-based rank values to Entrez gene-based ranks. Gene-based ranks are determined by taking the mean probe rank for each gene, sorting the mean rank values and then assigning a rank for each gene based on the sorted values. This allows results from RNA sequencing and Agilent microarray technologies, such as those provided by TCGA, to be analyzed with the drug-perturbed data of CMap in a standardized way at the gene level. A similar strategy has been applied in the R package gCMAP (18) 
CiDD workflow
A common workflow using CiDD is illustrated in Figure 2 The primary results of a CiDD execution are a biologically annotated candidate drug list and candidate cell lines for subsequent drug experimentation. (25) which is designed for both microarray and RNA sequencing differential expression analyses, CiDD identifies upand down-regulated genes. CiDD characterizes these results with biological pathways by performing gene set tests using the piano Bioconductor package (26) , while using gene sets defined by MSigDB.
Generation of a k-top scoring pairs (k-TSP) classifier
For generating a classifier that is robust across gene expression technologies, CiDD takes a non-parametric approach to classification and adopts an extension of the top scoring pairs (TSP) method (27) . Using the R package ktspair (28), CiDD generates a k-TSP classifier for predicting the status of the phenotype of interest on independent samples. The k-TSP algorithm is described in Supplementary Methods.
Candidate drug identification
CiDD connects gene expression changes associated with the phenotype of interest with candidate drug compounds that induce a negatively correlated (or "negatively connected") gene expression profile. CiDD compares the phenotype gene expression changes, termed a query signature, to rank-based gene expression profiles induced by CMap compounds. To compare rank-based gene expression profiles, CiDD implements nonparametric pattern-matching algorithms based on the Kolmogorov-Smirnov statistic as described by Lamb et al (14) . An enrichment score ranging from -1 to +1 provides a measure of the negative or positivity connectivity of a drug to the phenotype of interest. A permutation p-value provides a measure of significance for the enrichment scores. These algorithms and the resulting metrics are described in Supplementary Methods.
Cell line identification
CiDD first selects CCLE cell lines based on user-specified tissue types. Then, CiDD optionally identifies cell lines that contain user-specified mutations by interrogating CCLE mutation data derived from either targeted sequencing of common cancer genes or from Oncomap 3.0, which is a SNP array that genotypes samples at known cancer-related sites. Finally, CiDD runs its k- 
Results
We applied CiDD to identify candidate drugs to treat CRCs harboring BRAF V600E mutations using mutation and RNA-sequencing data from the TCGA colon and rectum projects. We also identified cell lines from CCLE that are representative of colorectal tumors with BRAF mutations, thus making them candidates for in vitro drug testing. We refer to these analyses as the TCGAderived analyses. The detailed commands to re-run these analyses are provided in Supplementary Methods. We then compared our systematic TCGA-derived analyses generated from CiDD with analyses performed using a previously published gene expression signature for BRAF V600E generated from CRC samples of the PETACC3 (Pan-European Trial Adjuvant Colon Cancer 3) clinical trial (15) . We refer to these published gene expression analyses as the PETACC3-derived analyses.
Identification of a BRAF V600E CRC gene expression signature
We used CiDD to identify 20 TCGA CRC samples with a BRAF V600E mutation and 149 BRAF wild-type samples with available Illumina GA RNA sequencing data. CiDD identified 63 upregulated and 170 down-regulated genes (log fold-change >= 2 and Benjamini Hochberg adjusted P-value <= 0.05) that generated a clustering of samples representative of BRAF mutation status as shown in Figure 3 .
We identified pathways associated with the BRAF signature through CiDD using Wilcoxonbased gene set tests (26) . For assessing significance of the gene set tests, CiDD performed 1000 runs of the differential expression analyses, permuting the BRAF mutant status of samples within each run. Fifteen KEGG gene sets were associated with the BRAF V600E status (FDR adjusted P-value <= 0.05). To incorporate PETACC3-derived pathways as part of the pathway analysis, a list of the top 20 pathways based on an average ranking within the TCGA and PETACC3-derived pathway lists is provided in Table 1 . Because raw gene expression data was not available for the PETACC3-derived signature, gene set tests were not performed. Instead, for the PETACC3-derived analysis, hypergeometric tests were applied to identify KEGG pathways enriched with genes from this signature. Twenty-seven KEGG pathways are enriched with genes from the PETACC3-derived signature (P-value <= 0.05). The pathway ordering in Table 1 reflects the average of the P-value ranks within each set (complete results are provided in Supplementary Results). These pathways are consistently related to CRC biology such as the top ranked pathway ("Colorectal Cancer") and other pathways related to TGFβ signaling known that the BRAF gene plays a role in controlling cellular proliferation and differentiation through regulation of the MAP kinase signaling pathway (29) , and the "MAPK Signaling Pathway" is also represented in the top ranked pathways.
Finally, we used CiDD to identify an 11-pair k-TSP classifier for predicting the BRAF V600E status of independent samples using the TCGA data set. The classifier gene pairs are listed in Supplementary Table S1 .
Validation of the TCGA-derived gene-pair classifier for predicting BRAF V600E status
In order to validate the TCGA-derived gene expression analyses, we compared the performance of a previously reported BRAF V600E gene expression classifier derived from the PETACC3 clinical trial (15) against the gene expression classifier that we identified from the TCGA data set.
The PETACC3-derived gene expression signature consists of 193 up-regulated and 92 downregulated probes. These probes correspond to 224 unique genes. The research group also developed a 64-gene TSP classifier (these genes are defined in Supplementary Table S2) based on Affymetrix probe IDs for predicting the BRAF V600E status of CRCs. We translated these probe IDs to Entrez gene IDs so the classifier could be applied to RNA sequencing and Agilent test data sets. To assess the robustness of their gene expression results, we applied the gene-based PETACC3-derived classifier to TCGA samples that were retrieved and annotated with BRAF mutation statuses by CiDD. When applied to TCGA RNA sequencing data, the PETACC3-derived classifier resulted in 93.3% sensitivity and 83.5% specificity for detecting BRAF V600E samples.
To assess the quality of the systematic TCGA-derived classifier generated by CiDD, we compared the performance of the TCGA-and PETACC3-derived classifiers on 3 independent data sets (see Table 2 ) -two have been previously published and are available in the Gene Expression Omnibus (30, 31) and the third is the CCLE data set. The sensitivity and specificity of both classifiers are comparable on the GSE35896 and GSE42284 data sets with the PETACC3-derived classifier exhibiting small improvements in specificity. The PETACC3-derived classifier achieved 100% sensitivity but only 30% specificity for BRAF status prediction on the CCLE large intestine data set. The TCGA-derived classifier had lower sensitivity (71%) but achieved better specificity (62%). These results suggest that the systematically obtained BRAF V600E 
classifier from CiDD is comparable to the published PETACC3-derived signature and that the TCGA-derived classifier may even have improved specificity for distinguishing BRAF wild-type cell lines from the BRAF mutant cell lines.
Candidate drug therapies for BRAF V600E CRC
Using both TCGA and PETACC3-derived gene expression signatures, CiDD identified candidate drugs to treat BRAF V600E CRCs. Drugs with a negative enrichment score and a permutation P-value less than 0.1 using the TCGA and PETACC3-derived gene expression signatures are listed in Table 3 and Supplementary Table S3 
Cancer cell lines that most resemble BRAF V600E CRC
In order to identify candidate cell lines for in vitro testing, CiDD analyzed data from the CCLE. We believe CiDD is the first framework that supports systematic drug discovery based on userspecified TCGA clinical phenotypes and molecular characteristics. CiDD allows researchers to perform the following: (1) assess whether or not a mutation or clinical phenotype is associated with a gene expression signature, (2) identify candidate drugs to target this gene expression signature, and (3) identify cell lines for subsequent in vitro drug experimentation. We have illustrated the power of such an approach in a meaningful application to CRCs with somatic mutations in BRAF. CiDD also offers utility to researchers simply wishing to interrogate and organize TCGA data, as it can be applied to create an inventory of available TCGA data with particular clinical or genomic features, such as available data sets or patients with particular mutations, independently of its drug identification capabilities.
One of the most crucial steps in the BRAF V600E analysis was identifying a gene expression signature associated with the BRAF V600E mutation and generating a classifier for predicting mutation status. In both of these cases, we showed that the signature and classifier of the CiDD framework are comparable to those identified from the published PETACC3-derived analyses (15) . Similarly to the PETACC3-derived signature and classifier, the CiDD-generated signature was composed of genes representative of known pathways associated with the BRAF V600E mutation, most notably the "MAPK Signaling Pathway", and the performance of the classifier on independent data sets generated from orthogonal gene expression technologies showed robustness. The advantage of CiDD analyses is that they are systematic studies of generally available datasets. We did not have to generate any of our own experimental data, and the gene expression analyses can be relatively easily replicated and repeated for other mutation or clinical phenotypes.
Once we validated the gene expression signature, we used CiDD to identify candidate compounds for tumors harboring the well-known BRAF V600E mutation. Since the initial communication of the presence of mutations in the kinase BRAF in cancer (33) , activating mutations have been described in several malignancies with different frequencies such as hairy cell leukemia (100%), melanoma (50-60%), thyroid carcinoma (30-50%) and CRC (10%) (34) .
The most frequently identified mutation is a valine-to-glutamic acid substitution at codon 600 (V600E) that activates the signaling cascade downstream of MEK and ERK (33) . Other mutations have been found at the same codon and are considered equivalent in terms of oncogenic activation (34) . Therefore, substantial efforts were invested on developing ATPcompetitive RAF inhibitors such as Vemurafenib and Dabrafenib to specifically target the MAPK pathway. Yet, the clinical success of BRAF inhibition has been variable and highly dependent on the tumor context. In this regard, Vemurafenib has demonstrated improvement in survival in patients diagnosed with stage IV melanomas harboring the BRAF V600E mutation (35) .
However, this degree of clinical benefit has not been observed in the same molecular context in CRCs and papillary thyroid cancers (36) . This is probably secondary to the intrinsic mechanisms of resistance to BRAF inhibition that are specific to the tumor context (34) . BRAF mutations in the context of metastatic CRCs have been associated with poor prognosis and an aggressive disease course contrasting with cases in early stages. In addition, they have a characteristic clinical phenotype consistent with older age at diagnosis, female gender, right-sided location and the presence of high levels of microsatellite instability (37, 38) . This has demonstrated specific activity against BRAF V600E mutant CRC cell lines and tumor xenografts. This set of experiments was performed using classical (Bortezomib) and novel (Carfilzomib) proteasome inhibitors and demonstrated similar activity. However, as opposed to EGFR feedback, proteasome inhibition seems to function independently of BRAF inhibition (32).
CiDD has been able to identify both types of compounds (EGFR and proteasome inhibitors) as candidate drugs through an agnostic approach, thus providing a biological validation of the value of CiDD as a screening tool to identify novel drugs to be tested and further developed in specific tumor subtypes.
CiDD also addresses the important issue of identifying appropriate publicly available cell lines as pre-clinical models for cancer researchers. Systematic comparisons between cancer cell lines and tumor samples from human tissues have documented substantial differences between the two, emphasizing the importance of making genomically informed choices when identifying cell lines as pre-clinical models of a tumor subtype (42) . The CCLE provides mutation and gene expression data that allow CiDD to make these molecularly informed decisions in selecting cell lines. In our BRAF V600E analysis, CiDD identified 7 large intestine cell lines harboring the BRAF V600E mutation. However, only 5 of the 7 were predicted to be BRAF V600E based on CiDD's gene expression classifier, suggesting heterogeneity among the BRAF V600E mutated cell lines. CiDD prioritized those cell lines into 2 groups for in vitro testing, proposing that 5 of the 7 BRAF V600E mutated large intestine cell lines more closely resemble the TCGA CRC BRAF V600E tumors at a gene expression level. We note however, that there may be a more ideal strategy for obtaining cell lines for in vitro testing for researchers wishing to deviate from the use of publicly available cell lines. The use of isogenic cell lines in drug experiments has been shown to be very effective, thus allowing for direct association of the sensitivity of a drug with a specific mutation (43) . As an example, in our BRAF mutant application, a researcher could obtain a colon cancer cell line that is wildtype for BRAF, then create a second identical cell line from this cell line except that it has a mutation in BRAF. Of course, these limitations apply more generally for these difficult scenarios and are not unique to CiDD. In fact, CiDD helps address these limitations by being easy to run and repeat to test multiple hypotheses quickly. Further, CiDD is a framework rather than a specific method per se.
As public databases evolve and expand, and as robust statistical methodologies mature for cross-platform expression-based signature identification, CiDD can be adapted to incorporate these improved components. In this sense, what we have demonstrated here is a "lower bound" of sorts, and we expect more powerful findings to emerge from such efficient systemsbased computation. Finally, the field of gene expression analysis, particularly for identifying signatures of cancer subtypes, has been criticized for failing to adhere to standards of repeatability (44) . Our software facilitates repeatability and even enables replication of findings with external data sets. In all of these aspects, we expect the community of cancer genomic researchers to benefit from, and further contribute to, this framework. Table 3 . Candidate drug compounds identified systematically by CiDD for BRAF V600E CRC based on the TCGA-derived gene expression signature. Nine drugs were identified having both a negative enrichment score and a maximum permutation P-value of 0.1. Three of these drugs (*) were also identified using the PETACC3-derived gene expression signature. 
